OnCoCross Co

OnCoCross Co EBIT per Employee

EBIT per Employee of OnCoCross Co (382150.KQ) as of Oct 17, 2026.

EBIT per Employee

-KRW

Last updated:

EBIT per Employee of OnCoCross Co is 2026 - KRW. EBIT per Employee of OnCoCross Co was 2025 - KRW. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OnCoCross Co Stock analysis

What does OnCoCross Co do? OnCoCross Co Ltd, headquartered in Seoul, South Korea, is a company focused on new drug research and development. It operates an AI-driven platform that analyzes gene expression data (Transcriptome) to match optimal disease treatments, primarily targeting rare diseases, cancer, and dementia. The company went public on 18 December 2024. OnCoCross Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OnCoCross Co stock

On Eulerpool you can find the complete historical development of EBIT per Employee OnCoCross Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's OnCoCross Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — OnCoCross Co

All Key Metrics — OnCoCross Co